AtriCure
ATRC
214 hedge funds and large institutions have $1.72B invested in AtriCure in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 85 increasing their positions, 70 reducing their positions, and 22 closing their positions.
1,005% more call options, than puts
Call options by funds: $906K | Put options by funds: $82K
21% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 70
9% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 22
0% more funds holding
Funds holding: 213 → 214 (+1)
0.29% more ownership
Funds ownership: 95.89% → 96.18% (+0.29%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $1.8B → $1.72B (-$75.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$17.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$9.24M |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$8.49M |
| 4 |
Amundi
Paris,
France
|
+$7.25M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$7.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$62.6M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$16.8M |
| 3 |
FAM
Fred Alger Management
New York
|
-$8.6M |
| 4 |
Millennium Management
New York
|
-$7.19M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.1M |
ATRC Hedge Fund Activity: Q3 2022 in Review
214 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q3 2022, worth a combined $1.72B — down 4.2% from $1.8B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ATRC positions and 22 closed out — a net gain of 2 holders — while 85 added to existing stakes and 70 trimmed.
The largest buyer was Champlain Investment Partners, adding an estimated $17.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $62.6M.
- 214 institutional investors held AtriCure (ATRC) as of Q3 2022, up from 213 in Q2 2022.
- Funds reported $1.72B of AtriCure stock for Q3 2022, down 4.2% quarter-over-quarter.
- 24 funds opened new AtriCure positions in Q3 2022 and 22 closed out, a net change of +2 holders.
- The largest AtriCure buyer in Q3 2022 was Champlain Investment Partners, an estimated $17.9M added.
- The largest AtriCure seller in Q3 2022 was T. Rowe Price Associates, an estimated $62.6M sold.
Based on aggregated 13F filings for Q3 2022.